What hurdles in delivering new modalities, like biologics, are you seeing? Delivery is really the key. We know, if we conduct experiments in the laboratory on cells, we can get incredible results. We ...

WALTHAM, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- ElevateBio, a technology-driven advanced therapy CDMO and gene editing services partner, today announced data from presentations at the American ...

For decades, drug developers have been confronted by the stubborn reality that most of the targets inside cells remain undruggable. Estimates suggest that as many as 85% of intracellular proteins ...

As genomic medicine advances beyond early proof-of-concept therapies, the field is facing an increasingly urgent challenge: delivery, not payload design, is now the primary bottleneck. While genetic ...

From CAR T to radiopharmaceuticals, we are generating new drug discovery modalities faster than you can say “deoxyribonucleic acid”. At this pace of innovation, even relatively recent advances, such ...